Xanadu Bio

Xanadu Bio is at the forefront of medical research, focusing on developing advanced treatments for cystic fibrosis. Co-founded by Dr. Marie Egan and Dr. Akiko Iwasaki, both esteemed professors at Yale University, the company leverages cutting-edge research in molecular biology and immunobiology. Dr. Egan's expertise lies in correcting the CFTR defect in cystic fibrosis through small molecules and gene editing, while Dr. Iwasaki's work focuses on immune defense mechanisms and mucosal vaccine strategies. The company operates in the biotechnology sector, targeting healthcare providers and patients affected by cystic fibrosis. Xanadu Bio's business model revolves around research and development, aiming to monetize through partnerships with pharmaceutical companies and healthcare institutions. The company generates revenue by advancing its proprietary treatments through clinical trials and securing licensing agreements. Keywords: cystic fibrosis, gene editing, small molecules, mucosal vaccines, biotechnology, healthcare, research, development, Yale University, immune defense.